NCT00666783View on ClinicalTrials.gov

An Efficacy and Safety Study of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in the Chinese Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

Not specified

Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
DRUG

palonosetron

receive a single, intravenous dose of palonosetron 0.25 mg, 30 minutes before receiving highly emetogenic chemotherapy.

DRUG

Granisetron

receive a single, intravenous dose of granisetron 3 mg, 30 minutes before chemotherapy.

Trial Locations (1)

710032

Xijng Hospital, Xi'an

All Listed Sponsors
lead

Xijing Hospital

OTHER

NCT00666783 - An Efficacy and Safety Study of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in the Chinese Cancer Patients | Biotech Hunter | Biotech Hunter